Immunotherapy is moving earlier in resectable NSCLC
Early-stage non-small cell lung cancer has never been a low-risk disease. Even when the tumor can be removed surgically, distant relapse has remained a major threat, and that reality has driven the shift toward treatment strategies that begin before the operating room and continue after it. The review frames immune-checkpoint blockade as part of that shift, moving immunotherapy from advanced disease into the curative-intent setting where micrometastatic disease may be present long before it is visible on imaging.
The central message is direct: surgery alone is no longer the only serious option being tested in resectable NSCLC. Neoadjuvant, adjuvant, and perioperative immune-checkpoint inhibitor regimens are now being examined as ways to improve long-term disease control, and the field has expanded quickly enough to include monotherapy, combination approaches, and chemotherapy backbones. For oncologists, the important question is no longer whether immunotherapy belongs in early lung cancer research. The question is how best to sequence it, for whom, and with what surrogate and survival endpoints.
Why earlier immune intervention matters in operable lung cancer
The biological rationale is straightforward. If residual malignant cells remain after surgery or are already circulating or seeded outside the primary tumor bed, then a systemic therapy that activates antitumor immunity may do what surgery cannot: address disease at a microscopic level. In resectable NSCLC, that logic has made preoperative and postoperative immune therapy attractive, especially because recurrence patterns in early disease can still be distant rather than purely local.
This is where neoadjuvant treatment has special appeal. Immune activation before tumor removal may expose the immune system to intact tumor antigens, potentially broadening the antitumor response. Adjuvant therapy, by contrast, is intended to eliminate residual disease after resection, while perioperative strategies try to combine both moments of intervention into one coordinated plan. Each approach has a different therapeutic logic, but all are aimed at the same clinical problem: relapse after apparently curative surgery.
A crowded field of regimens with different strengths and limitations
The review emphasizes that immune-checkpoint inhibitors have been explored in several ways in early NSCLC. Some studies have tested ICI monotherapy, while others have combined immunotherapy with chemotherapy. These regimens have been evaluated in adjuvant, neoadjuvant, and perioperative settings, creating a field that is scientifically active but not yet fully settled.
This breadth is also the source of the current challenge. Each treatment sequence can alter pathologic response, operative timing, postoperative recovery, and the ability to judge whether a short-term endpoint truly predicts durable benefit. Pathologic response may be encouraging, but the real goal is survival, and the review makes clear that the translation from trial endpoint to patient outcome remains an active area of study. In curable-intent lung cancer, a favorable response on paper only matters if it leads to fewer relapses and longer life.
One sentence captures the tension in the field:
Short-term response cannot be allowed to masquerade as long-term cure.
Biomarkers may determine who benefits most
A major theme in the review is patient selection. Early-stage NSCLC is not biologically uniform, and the same treatment sequence will not necessarily produce the same effect across all tumors or all patients. Investigators are working to identify biomarkers that could predict response to immunotherapy, a step that would make these regimens more precise and less empiric.
That search has practical consequences. If biomarkers can identify tumors most likely to respond, clinicians may be able to avoid unnecessary toxicity, prevent futile delays to surgery, and reserve the most intensive approaches for the patients most likely to benefit. Without that kind of stratification, the field risks treating early lung cancer as a single disease when it is really a collection of distinct immune and molecular states.
The review does not claim that one biomarker has solved the problem. Instead, it presents biomarker development as one of the defining tasks of the current era. The goal is not simply to measure response, but to match treatment intensity to biology.
Endpoints are evolving faster than practice
The review also points to a persistent methodological problem in early lung cancer research: trial endpoints are moving targets. In advanced disease, radiographic progression and survival are often used to guide therapy decisions. In resectable disease, investigators also have to account for surgical feasibility, pathologic regression, and the possibility that a therapy improves an intermediate endpoint without proving a durable survival advantage.
That is why the translation of trial results into practice requires caution. A regimen can appear promising in a neoadjuvant setting because it induces a stronger tumor response before surgery, yet still leave unanswered questions about recurrence, long-term survival, and the durability of immune activation. Adjuvant treatment raises a different set of issues, including treatment adherence after major surgery and the balance between benefit and postoperative burden. Perioperative strategies may combine the advantages of both, but they also increase complexity.
For clinicians, the practical consequence is clear. Treatment selection in resectable NSCLC now depends not only on stage and resectability, but also on whether the anticipated benefit is pathologic, disease-free, or overall survival, and whether the patient can realistically complete the intended sequence.
The next phase will depend on matching strategy to biology
The review presents early-stage immunotherapy as a major development in lung cancer care, but it does not treat the field as finished. The promise is substantial, yet several questions remain unresolved: which patient subsets truly need neoadjuvant therapy, which benefit more from adjuvant treatment, and which may be best served by a perioperative plan that spans both. Those decisions will depend on better biomarkers, more mature survival data, and clearer understanding of how to balance benefit against toxicity and surgical timing.
What emerges most strongly is the sense that resectable NSCLC is no longer governed solely by the scalpel. Immunotherapy has entered the curative-intent setting because surgery alone has not been enough to eliminate the risk of distant relapse. The field now has to prove not just that immune therapy can shift early endpoints, but that it can change the long-term course of disease in a way that matters to patients after resection. The remaining work is clinical, biological, and methodological at the same time: determine who benefits, when treatment should begin, and which endpoint best reflects real survival gain.